

# Two Abstracts Featuring Advaxis' Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting

PRINCETON, N.J.--(BUSINESS WIRE)-- [Advaxis, Inc.](#) (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced two abstracts were selected for presentation at the 32<sup>nd</sup> annual [Society for Immunotherapy of Cancer](#) (SITC) meeting. The conference is renowned for its scientific exchange, education and mission to improve patient outcomes through advancement of science and the cancer immunotherapy field.

Both poster presentations feature Advaxis' proprietary *Listeria monocytogenes* (*Lm*)-based technology. The first presentation, "ADXS-PSA immunotherapy increases the magnitude and quality of prostate cancer antigen-specific T cell responses in patients with metastatic castration-resistant prostate cancer," will feature data from Advaxis' clinical trial with ADXS-PSA. The presentation examines the frequency and functionality of the T cell response not only specific to its target antigen, but to other prostate cancer antigens.

This data builds on what was presented at CICON 2017 and is the first time that an *Lm*-based vector targeting a self protein – PSA – can increase the frequency and functionality of T cells reactive to PSA as well as to other prostate cancer antigens. As one of Advaxis' four focus franchises, prostate cancer could be a significant value creator to expand the *Lm* platform into new tumor types. The data will be presented by Sandy Hayes, Ph.D., senior director of research and biomarker lead at Advaxis.

The second poster presentation, "*Listeria monocytogenes*-based immunotherapies alter the suppressive phenotype of intratumoral regulatory T cells," spotlights preclinical data pointing to a potential key mechanism for inducing and sustaining infiltration of tumor-specific T cell effectors. The data will be presented by Rachelle E. Kosoff, Ph.D., senior scientist of research at Advaxis.

"We're grateful to be sharing these meaningful findings with the rest of the immunotherapy community," said Dr. Robert Petit, chief scientific officer at Advaxis. "Each poster presentation allows members of our field to discuss new findings and approaches, with the goal of bringing improved treatment options to patients."

SITC takes place at Maryland's National Harbor in the Gaylord National Hotel and Convention Center from Nov. 8 – 12, 2017. The conference focuses on improving

outcomes for current and future patients with cancer by incorporating strategies based on basic and applied immunotherapy.

To learn more about Advaxis and its immunotherapy clinical programs, visit [www.advaxis.com/clinical-trials](http://www.advaxis.com/clinical-trials).

### **About Advaxis, Inc.**

Advaxis, Inc., located in Princeton N.J., is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary *Lm*-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated *Listeria monocytogenes* (*Lm*) bioengineered to secrete antigen/adjuvant fusion proteins. These *Lm*-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T-cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and pre-clinical development: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

To learn more about Advaxis, visit [www.advaxis.com](http://www.advaxis.com) and connect on [Twitter](#), [LinkedIn](#), [Facebook](#), and [YouTube](#).

### **Advaxis Forward-Looking Statement**

This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis' ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis' proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis' SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2016, which is available at <http://www.sec.gov>. Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20170919005336/en/>

### **Company:**

[Advaxis, Inc.](#)

Noelle Heber, 609-250-7575

Sr. Director Corporate Communications and Government Affairs

[Heber@advaxis.com](mailto:Heber@advaxis.com)

or

### **Media:**

[Stern Strategy Group](#)

Brian Hyland, 908-325-3891

[Bhyland@sternstrategy.com](mailto:Bhyland@sternstrategy.com)

or

Rachel Auerbach, 908-325-3898

[Rauerbach@sternstrategy.com](mailto:Rauerbach@sternstrategy.com)

or

**Investors:**

[LifeSci Advisors](#)

Hans Vitzthum, 212-915-2568

[Hans@lifesciadvisors.com](mailto:Hans@lifesciadvisors.com)

Source: Advaxis, Inc.